Clinical trial NCT00843609: International Navigator Hypoglycaemia Study
Official title: International Navigator Hypoglycaemia Study: Evaluation of the Incidence and Duration of Hypoglycaemia Using the Freestyle Navigator® Continuous Glucose Monitoring System
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus, Type 1
Hypoglycemia
Keywords: diabetes mellitus, type 1
hypoglycemia
continuous glucose monitoring
HbA1c
glycemic variability
Lead sponsor: University Medical Centre Ljubljana
Sponsor class: OTHER
Collaborators: name: Karolinska Institutet
name: Schneider Children's Medical Center, Israel
First posted: 2009-02-13
Enrollment: 122
Sex: ALL
Minimum age (years): 10
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if the incidence and duration of hypoglycaemia (low blood sugar) is reduced through the use of the FreeStyle Navigator Continuous Glucose Monitoring System in people with Type 1 diabetes mellitus at good glycemic control. The investigators hypothesize that the access to real-time continuous glucose concentration data along with alarms will enable people with type 1 diabetes at reasonable metabolic control to reduce the time spent in hypoglycaemia.

Detailed description: Background:

Real-time continuous glucose monitoring is expected to allow patients to reduce glycaemic fluctuations and to improve their ability to achieve tight glycaemic control without an increase in the incidence or fear of hypoglycaemia through the availability of high fidelity real-time glucose data and alarms throughout the day. As well as in adults, this may be particularly important in both children and adolescents with type 1 diabetes mellitus (T1DM).

Study Overview:

This is a multicentre, prospective, randomised, controlled, intervention study, being conducted at 3 study centres; Ljubljana in Slovenia, Tel Aviv in Israel and Stockholm in Sweden.

The aim is to enroll 100 subjects (50 adult and 50 paediatric), but enrolling up to 120 eligible subjects to allow for dropouts. The subject population will be randomly assigned 50:50 to either the control group or intervention group.

Subjects will be asked to participate for 7 months, consisting of a one-month 'run-in' period on SMBG followed by a 6-month test period. Enrolment will take place within a 16-week period. A blood sample will be taken for centralized baseline measurement of HbA1c. To be included in the study a subject must have an HbA1c level at inclusion below 7.5 % All subjects will undergo a one-month run-in period. Each subject will be given a FreeStyle blood glucose meter and strips to perform self monitoring of blood glucose (SMBG) according to their standard glycaemic management regime, as advised by their health care professional (HCP).

Subjects will then be required to return to the clinic at the end of the run-in period to have another blood sample taken for centralized measurement of HbA1c and to be randomly assigned to Group 1 (intervention) or Group 2 (control) for the next 6-month test period.

Group 1 will be required to use the FreeStyle Navigator CGM to manage their glycaemic control, wearing individual sensors for a series of five day durations, for the next six months.

Group 2 will continue in the study for the next 6 months using SMBG to manage their glycaemic control with the FreeStyle meter and strips provided. Every second week the subject will wear a 'masked' FreeStyle Navigator sensor for 5 days. Subjects will be encouraged to alternate the days that they wear the FreeStyle Navigator sensors, so that data is obtained from days in both the week and weekend.

Subjects will return to the clinic at 3 months and 6 months (after entering the study test-phase) for centralized HbA1c measurement. Subjects (and parents of paediatric subjects) within the intervention group will also be asked to complete a subject satisfaction questionnaire on their experience with the device.

Eligibility criteria: Inclusion Criteria:

* Subject with Type 1 diabetes (\> 1year since diagnosis)
* CSII or MDI
* HbA1c at inclusion \< 7.5 %
* No concomitant diseases that influence metabolic control
* No current use of CGM

Exclusion Criteria:

* Subject has known allergy to medical grade adhesives
* Subject has a medical condition, which in the Investigator's opinion, may compromise patient safety
* Subject is participating in another study of a glucose monitoring device or drug that could affect glucose measurements or glucose management
* Subject is currently using another CGM device or has used real-time continuous glucose monitoring in the previous 4 weeks
* Subject is receiving peritoneal dialysis solutions containing icodextrin
* Female subject who is pregnant or planning to become pregnant within the planned study duration

Primary outcomes:
measure: Reduction in time spent in hypoglycaemia, defined as continuous glucose <3.5mmol/l (63mg/dl) (with or without symptomatic hypoglycaemia).
timeFrame: 6 months after randomisation
Secondary outcomes:
measure: No concomitant rise in HbA1c
timeFrame: 6 months after randomization
measure: Glycaemic variability
timeFrame: 6 months after randomization
measure: Frequency and area under the curve (AUC) of hypoglycaemia
timeFrame: 6 months after randomization
measure: Quality of Life measures (Fear of Hypoglycaemia score and subject satisfaction questionnaire);
timeFrame: 6 months after randomization
Other outcomes:
Locations:
city: Petah Tikva
country: Israel
facility: Schneider Children's Medical Center of Israel
city: Ljubljana
country: Slovenia
facility: UMC Ljubljana - University Children's Hospital
city: Stockholm
country: Sweden
facility: Karolinska Institutet
Study officials:
affiliation: UMC Ljubljana
name: Tadej Battelino, Prof.
role: PRINCIPAL_INVESTIGATOR
References: